LINC01620

Across TCGA pan-cancer cohorts, LINC01620 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LINC01620’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LINC01620 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01620 is over-expressed in tumor, although a few such as CHOL and LUAD show the opposite, repressed pattern.

KIRC, CHOL, and HNSC are the cancer types where LINC01620 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01620 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	+0.052	<.001	9	view →
CHOL	Male	All	−0.241	<.001	4	view →
HNSC	All	All	+0.027	.019	4	view →
LUAD	Female	All	−0.050	.003	2	view →
LUSC	Female	All	−0.045	.031	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LINC01620–KIRC

Open the KIRC breakdown →